Merck KGaA acquires Chord Therapeutics and with it CRD 1 (cladribine) for new indications.
Read time: 1 mins
Published:28th Dec 2021
Merck KGaA, a leading science and technology company, announced a strategically focused expansion of its neurology pipeline with the acquisition of the rights to develop cladribine for the treatment of generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD).
Merck entered into an agreement to secure the global rights by acquiring Chord Therapeutics, a Swiss-based biotech company focused on rare neuroinflammatory diseases.